D Santini

Summary

Affiliation: University Campus Bio-Medico
Country: Italy

Publications

  1. ncbi Fatal thrombocytopenia and thrombocytopathia: an unusual onset of non-small cell lung cancer
    G Tonini
    Oncology Department, Campus Bio Medico University, Rome, Italy
    Onkologie 26:272-4. 2003
  2. pmc Surviving acute myocardial infarction: survivin expression in viable cardiomyocytes after infarction
    D Santini
    Department of Oncology, University Campus Bio Medico, Rome, 00100 Italy
    J Clin Pathol 57:1321-4. 2004
  3. pmc Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients
    G Tonini
    Medical Oncology, University Campus Bio Medico, Rome, Via Emilio Longoni 83, 00155 Rome, Italy
    Br J Cancer 92:2225-32. 2005
  4. ncbi Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients
    B Vincenzi
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Ann Oncol 17:835-41. 2006
  5. ncbi Denosumab: the era of targeted therapies in bone metastatic diseases
    D Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Curr Cancer Drug Targets 9:834-42. 2009
  6. pmc Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw
    Bruno Vincenzi
    Department of Medical Oncology, Campus Bio Medico University of Rome, Rome, Italy
    J Hematol Oncol 5:56. 2012
  7. pmc Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options
    Bruno Vincenzi
    Department of Medical Oncology, Università Campus Bio Medico, Rome, Italy
    Clin Sarcoma Res 3:6. 2013
  8. doi 'Old' and 'new' drugs for the treatment of cancer pain
    Daniele Santini
    University Campus Bio Medico Roma, Oncologia Medica, Rome, Italy
    Expert Opin Pharmacother 14:425-33. 2013
  9. doi Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma
    Daniele Santini
    Oncologia Medica, Università Campus Bio Medico, Roma, Italy
    Expert Rev Anticancer Ther 12:1283-8. 2012
  10. doi Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study
    Daniele Santini
    Department of Medical Oncology, Campus Bio Medico University of Rome, Rome, Italy
    Lancet Oncol 13:1020-4. 2012

Detail Information

Publications145 found, 100 shown here

  1. ncbi Fatal thrombocytopenia and thrombocytopathia: an unusual onset of non-small cell lung cancer
    G Tonini
    Oncology Department, Campus Bio Medico University, Rome, Italy
    Onkologie 26:272-4. 2003
    ..Although bone marrow is a common site of micrometastases for non-small cell lung cancer (NSCLC), thrombocytopathia and hemorrhagic diathesis are rare causes of death...
  2. pmc Surviving acute myocardial infarction: survivin expression in viable cardiomyocytes after infarction
    D Santini
    Department of Oncology, University Campus Bio Medico, Rome, 00100 Italy
    J Clin Pathol 57:1321-4. 2004
    ..Both proapoptotic and antiapoptotic factors contribute to the delicate balance between death and survival. The survivin pathway has emerged as essential in the control of apoptosis, although its role in heart disease is unknown...
  3. pmc Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients
    G Tonini
    Medical Oncology, University Campus Bio Medico, Rome, Via Emilio Longoni 83, 00155 Rome, Italy
    Br J Cancer 92:2225-32. 2005
    ..In particular, patients with high nuclear Survivin staining showed a longer survival, whereas patients with high cytoplasmic Survivin staining had a shorter overall survival...
  4. ncbi Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients
    B Vincenzi
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Ann Oncol 17:835-41. 2006
    ....
  5. ncbi Denosumab: the era of targeted therapies in bone metastatic diseases
    D Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Curr Cancer Drug Targets 9:834-42. 2009
    ..The clinical data that will be reported in this review represent the first step in a path that will conduct us to explore new horizons in the field of bone health care in cancer patients...
  6. pmc Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw
    Bruno Vincenzi
    Department of Medical Oncology, Campus Bio Medico University of Rome, Rome, Italy
    J Hematol Oncol 5:56. 2012
    ..These data demonstrated for the first time that the anti-angiogenic properties of bisphosphonates are directly linked to B-ONJ pathogenesis and serum VEGF levels could represent an effective early predictive marker...
  7. pmc Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options
    Bruno Vincenzi
    Department of Medical Oncology, Università Campus Bio Medico, Rome, Italy
    Clin Sarcoma Res 3:6. 2013
    ..We surveyed the natural history of bone metastases in patients affected by soft tissue sarcoma (STS)...
  8. doi 'Old' and 'new' drugs for the treatment of cancer pain
    Daniele Santini
    University Campus Bio Medico Roma, Oncologia Medica, Rome, Italy
    Expert Opin Pharmacother 14:425-33. 2013
    ....
  9. doi Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma
    Daniele Santini
    Oncologia Medica, Università Campus Bio Medico, Roma, Italy
    Expert Rev Anticancer Ther 12:1283-8. 2012
    ....
  10. doi Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study
    Daniele Santini
    Department of Medical Oncology, Campus Bio Medico University of Rome, Rome, Italy
    Lancet Oncol 13:1020-4. 2012
    ..We designed a pilot single-centre study to assess the effects of aprepitant-a neurokinin receptor inhibitor-for management of severe pruritus induced by biological drugs...
  11. doi Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study
    D Santini
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    Ann Oncol 23:2072-7. 2012
    ..Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC...
  12. doi Perspectives in the elderly patient: benefits and limits of bisphosphonates and denosumab
    Daniele Santini
    University Campus Bio Medico, Rome, Italy
    Recent Results Cancer Res 192:171-85. 2012
    ..For this reason, this chapter will discuss the results of current therapies in this clinical setting...
  13. doi The role of bone microenvironment, vitamin D and calcium
    Daniele Santini
    University Campus Bio Medico, Via Alvaro del Portillo, Rome, Italy
    Recent Results Cancer Res 192:33-64. 2012
    ....
  14. pmc Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
    Fotios Loupakis
    U, O, Oncologia Medica 2 Universitaria, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori and Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina, Universita di Pisa, Italy
    BMC Cancer 11:247. 2011
    ..Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identified yet. Specific VEGF polymorphisms may affect gene transcription and therefore indirectly influence the efficacy of bevacizumab...
  15. ncbi Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients
    Daniele Santini
    Medical Oncolog, University Campus Bio Medico, Rome, Italy
    Clin Cancer Res 13:4482-6. 2007
    ....
  16. ncbi New developments of aminobisphosphonates: the double face of Janus
    D Santini
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    Ann Oncol 18:vi164-7. 2007
    ..In vivo preclinical and preliminary clinical data indicate that BPs may prevent cancer treatment-induced bone loss and the onset of malignant bone disease in patients with early-stage cancer...
  17. ncbi Zoledronic acid in the management of metastatic bone disease
    Daniele Santini
    University Campus Bio Medico, Medical Oncology, Via Emilio Longoni 69, 00155 Rome, Italy
    Expert Opin Biol Ther 6:1333-48. 2006
    ..Renal safety is an important consideration for oncologists who are treating patients with bisphosphonates. This issue and the other topics relating to the safety of bisphosphonates are discussed in this review...
  18. pmc Mucin 2 (MUC2) and mucin 5 (MUC5) expression is not associated with prognosis in patients with radically resected ampullary carcinoma
    D Santini
    Università Campus Bio Medico, Via E Longoni no degrees 83, 00155 Rome, Italy
    J Clin Pathol 60:1069-70. 2007
  19. ncbi A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients
    D Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Ann Oncol 18:576-80. 2007
    ..The goals of this phase I study were to determine the maximum-tolerated dose of this combination and to describe the dose-limiting toxic effects (DLT) and the safety profile of this way of administration...
  20. ncbi Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Oncology 69:27-34. 2005
    ..The aim of the study was to define the feasibility and efficacy of Xelox (capecitabine and oxaliplatin) administered through a new and original schedule in advanced pretreated colorectal cancer (CRC) patients...
  21. ncbi Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Via Emilio Longoni, 69, 00155 Rome, Italy
    Cancer Chemother Pharmacol 59:613-20. 2007
    ..The aim of the present study was to define the feasibility and efficacy of XELOX administered through a new chronomodulated schedule in untreated advanced colorectal cancer (CRC) patients...
  22. ncbi Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates
    Daniele Santini
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    Nat Clin Pract Oncol 3:325-38. 2006
    ..We briefly discuss identification of new molecular targets of bisphosphonates from genomic and proteomic analysis, and highlight the cellular consequences of drug-related enzyme inhibition...
  23. pmc Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial
    D Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    BMC Cancer 6:125. 2006
    ..The secondary objective was to measure the time to disease progression and the survival time...
  24. ncbi Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours
    Daniele Santini
    Clinical Oncology, University Campus Bio Medico, 00155 Rome, Italy
    Oncol Rep 15:1351-7. 2006
    ..Future clinical trials should be designed to prospectively evaluate the prognostic role of reduction of betaCTX and VEGF in response to ZOL to predict clinical and skeletal outcome...
  25. pmc Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    BMC Cancer 6:42. 2006
    ....
  26. ncbi An increase of CA 19.9 as the first clinical sign of ileocecal valve metastasis from breast cancer
    Daniele Santini
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    In Vivo 20:165-8. 2006
    ..CONCLUSION: This is the first report in the literature of an ileocecal valve metastasis from breast cancer diagnosed by an increase of CA 19.9, which is a marker of primary colorectal carcinoma...
  27. ncbi Anaphylaxis to dexrazoxane (ICRF-187) following three previous uncomplicated infusions
    V Leoni
    Università Campus Bio Medico Via Emilio Longoni, 83 00155 Rome Italy
    Allergy 59:241. 2004
  28. doi Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer
    D Santini
    Department of Medical Oncology, University Campus Bio Medico, via Emilio Longoni 81, 00155 Rome, Italy
    Ann Oncol 19:724-8. 2008
    ....
  29. ncbi Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs?
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome
    Recent Pat Anticancer Drug Discov 1:383-96. 2006
    ..The translation into the clinical setting of the preclinical evidence of an antiangiogenic power of these drugs is becoming an imperative need and should represent the objective of future clinical trials...
  30. ncbi Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity
    D Santini
    Division of Oncology, Campus Bio Medico University, Rome, Italy
    Ann Oncol 11:479-81. 2000
    ..Gemcitabine is an antimetabolic drug for solid tumors. Although its pharmacokinetics as well as its side-effects are well known, paroxysmal atrial fibrillation associated to the administration of this drug has not yet been described...
  31. pmc Targeting bone metastases starting from the preneoplastic niche: home sweet home
    Daniele Santini
    Department of Medical Oncology, University Campus Bio Medico, Via Alvaro del Portillo 200, 00128, Rome, Italy
    Breast Cancer Res 13:111. 2011
    ....
  32. pmc Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients
    Daniele Santini
    Department of Medical Oncology, University Campus Bio Medico of Rome, Rome, Italy
    PLoS ONE 6:e19234. 2011
    ..RANKL stimulates migration of RANK-expressing tumor cells in vitro, conversely inhibited by OPG...
  33. doi New molecular targets in bone metastases
    D Santini
    Medical Oncology Department, University Campus Bio Medico, Via Alvaro del Portillo 200, Rome, Italy
    Cancer Treat Rev 36:S6-S10. 2010
    ..Targeting the bone by preventing skeletal related events (SREs) and bone metastases has major clinical impact in improving survival in bone metastatic patients and in preventing disease relapse in adjuvant setting...
  34. ncbi Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC)
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Curr Cancer Drug Targets 11:123-9. 2011
    ..The aim of this study was to retrospectively determine patients' outcome according to the expression of hENT1 in tumoral cells of patients receiving gemcitabine-based therapy...
  35. ncbi Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Curr Cancer Drug Targets 10:46-54. 2010
    ..The clinical data that will be reported in this review represent the first step in a path that will conduct us to explore new horizons in the field of adjuvant and metastatic cancer therapies...
  36. doi Are bisphosphonates the suitable anticancer drugs for the elderly?
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy
    Crit Rev Oncol Hematol 69:83-94. 2009
    ..If the results of these ongoing clinical trials will be positive, the indications for bisphosphonates could increase, including also elderly patients...
  37. doi High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice
    Daniele Santini
    Department of Oncology, University Campus Bio Medico, Rome, Italy
    Oncologist 13:1270-5. 2008
    ..Nevertheless, most experiences were conducted on samples from primaries. The aim of this study was to evaluate the grade of concordance in terms of KRAS status between primaries and related metastases...
  38. ncbi The antineoplastic role of bisphosphonates: from basic research to clinical evidence
    D Santini
    Interdisciplinary Center for Biomedical Research CIR, Oncology, University Campus Bio Medico, Rome, Italy
    Ann Oncol 14:1468-76. 2003
    ....
  39. pmc Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma
    D Santini
    University Campus Bio Medico University, Via Emilio Longoni, 83, 00155 Rome, Italy
    J Clin Pathol 58:159-65. 2005
    ..There is a lack of data in the literature concerning the identification of potential prognostic factors in ampullary adenocarcinoma...
  40. ncbi Up-regulation of proliferating cell nuclear antigen (PCNA) is closely associated with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer
    M Branca
    Unità Citoistopatologia, Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità ISS, Rome, Italy
    Eur J Obstet Gynecol Reprod Biol 130:223-31. 2007
    ..The E7 oncoprotein of high-risk human papillomavirus (HPV) is known to activate PCNA, shown to be up-regulated in CIN and cervical cancer (CC), but still incompletely studied as an intermediate endpoint marker in this disease...
  41. ncbi Upregulation of nuclear factor-kappaB (NF-kappaB) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus or disease outcome in cervical cancer
    M Branca
    Unità Citoistopatologia, Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità ISS, Rome, Italy
    Diagn Cytopathol 34:555-63. 2006
    ..e., E7-mediated impaired nuclear translocation of cytoplasmic NF-kappaB, and E6-conditioned attenuated NF-kappaB (p65)-dependent transcriptional activity...
  42. ncbi Down-regulation of E-cadherin is closely associated with progression of cervical intraepithelial neoplasia (CIN), but not with high-risk human papillomavirus (HPV) or disease outcome in cervical cancer
    M Branca
    Unità Citoistopatologia, Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Saniti ISS, Rome, Italy
    Eur J Gynaecol Oncol 27:215-23. 2006
    ....
  43. ncbi Upregulation of telomerase (hTERT) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus, virus persistence, or disease outcome in cervical cancer
    M Branca
    Unità Citoistopatologia, Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità ISS, Rome, Italy
    Diagn Cytopathol 34:739-48. 2006
    ..g. Hybrid Capture 2 for HPV), should provide an ideal screening tool capable of high-performance detection of CIN lesions...
  44. pmc Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes
    G Perrone
    Department of Anatomical Pathology, Campus Bio Medico University, Via Alvaro del Portillo 200, Rome, Italy
    Eur J Histochem 54:e38. 2010
    ....
  45. doi Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients
    B Vincenzi
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    Ann Oncol 20:78-83. 2009
    ..Promyelocytic leukemia (PML) tumor suppressor gene plays a key role in acute PML pathogenesis but its involvement in pathogenesis and prognosis of solid cancers has not been defined yet...
  46. pmc COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables
    G Perrone
    Surgical Pathology, Campus Bio Medico University, Rome, Italy
    J Clin Pathol 59:492-6. 2006
    ..Objective: To investigate by immunohistochemistry the expression of COX-2 and the angiogenesis process in a series of primary untreated ampullary carcinomas...
  47. doi Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients
    B Vincenzi
    Department of Medical Oncology, University Campus Bio Medico, Rome
    Ann Oncol 22:1141-6. 2011
    ....
  48. pmc Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial
    B Vincenzi
    Medical Oncology, Campus Bio Medico University, Via Emilio Longoni, 69, 00155 Rome, Italy
    Br J Cancer 94:792-7. 2006
    ..Cetuximab has clinically significant activity even in heavily pretreated colorectal cancer patients progressed after both oxaliplatin and irinotecan-based chemotherapy regimens...
  49. doi Update on capecitabine alone and in combination regimens in colorectal cancer patients
    N Silvestris
    Medical Oncology Department, National Cancer Institute Giovanni Paolo II, Via Hahnemann 10, Bari, Italy
    Cancer Treat Rev 36:S46-55. 2010
    ....
  50. ncbi The antineoplastic treatment in the elderly
    B Vincenzi
    Università Campus Bio Medico, Rome, Via E Longoni 69, Rome, Italy
    Clin Ter 153:207-15. 2002
    ....
  51. pmc Down-regulated nucleoside diphosphate kinase nm23-H1 expression is unrelated to high-risk human papillomavirus but associated with progression of cervical intraepithelial neoplasia and unfavourable prognosis in cervical cancer
    M Branca
    Unità Citoistopatologia, Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità ISS, Rome, Italy
    J Clin Pathol 59:1044-51. 2006
    ..Of the six known members, nm23-H1 is the most frequently studied potential anti-metastatic gene in cervical cancer. However, the possible molecular links to oncogenic human papillomavirus (HPV) are completely unexplored as yet...
  52. ncbi Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients
    G Tonini
    University of Campus Bio Medico, Rome, Italy
    J Biol Regul Homeost Agents 16:105-9. 2002
    ..Oxaliplatin, a third-generation platinum analogue, is a novel compound with proven anti-tumor activity in colorectal cancer. Moreover, oxaliplatin appears to be relatively well tolerated and easy to handle, even on an outpatient basis...
  53. ncbi Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions
    C C Quattrocchi
    Centro Interdisciplinare per la Ricerca Bio Medica, Department of Radiology, Università Campus Bio Medico di Roma, Via Longoni 47, I 00155, Roma, Italy
    Radiol Med 112:1049-59. 2007
    ....
  54. doi Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
    D Santini
    Department of Medical Oncology, Università Campus Bio Medico, Rome
    Ann Oncol 23:2313-8. 2012
    ..This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab-based therapy...
  55. pmc Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
    V Catalano
    Department of Medical Oncology, Azienda Ospedaliera Ospedale San Salvatore, Pesaro, Italy
    Br J Cancer 99:1402-7. 2008
    ....
  56. pmc Tumour proliferation, angiogenesis, and ploidy status in human colon cancer
    E Cristi
    Surgical Pathology, Campus Bio Medico University, Via Emilio Longoni, Rome 83 00155, Italy
    J Clin Pathol 58:1170-4. 2005
    ..To gain further insight into the effects of microvessel density and VEGF expression in colon cancer, their relation with tumour proliferation, ploidy status, and p53 expression was investigated in colon cancer...
  57. ncbi New perspectives: role of Sunitinib in breast cancer
    M E Fratto
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    Clin Ter 162:251-7. 2011
    ..We overviewed the most relevant studies concerning Sunitinib in metastatic BC...
  58. ncbi COX-2 expression in lobular in situ neoplasia of the breast: correlation with histopathological grading system according to the Tavassoli classification
    G Perrone
    Surgical Pathology, Oncology Unit, University Campus Bio Medico, La Sapienza University, Rome, Italy
    Histopathology 51:33-9. 2007
    ....
  59. ncbi Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)
    S Cascinu
    Department of Medical Oncology, Azienda Ospedaliera di Parma, Italy
    Ann Oncol 13:716-20. 2002
    ..To evaluate the safety and efficacy of the novel raltitrexed/oxaliplatin combination (TOMOX) as first-line chemotherapy for patients with advanced colorectal cancer...
  60. ncbi Cell cycle alterations and lung cancer
    B Vincenzi
    Medical Oncology, Campus Bio Medico University, Rome, Italy
    Histol Histopathol 21:423-35. 2006
    ....
  61. ncbi COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features
    G Perrone
    Surgical Pathology, Campus Bio Medico University, Rome, Italy
    Histopathology 46:561-8. 2005
    ....
  62. doi Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer
    V Catalano
    Department of Oncology, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Presidio San Salvatore, Pesaro, Italy
    Ann Oncol 23:135-41. 2012
    ....
  63. ncbi Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer
    G Perrone
    Service of Histopathology, Campus Bio Medico University, Rome, Italy
    Cancer Lett 208:227-34. 2004
    ..0001 and P=0.009). Our data confirm the central role of VEGF in angiogenesis and suggest direct correlations among p53, bcl-2 and VEGF expression in colon cancer...
  64. ncbi Prevention of radiotherapy-induced emesis
    G Tonini
    Division of Medical Oncology, University Campus Bio Medico, Rome, Italy
    J Exp Clin Cancer Res 22:17-22. 2003
    ..We herewith present a brief summary of Clinical practice guidelines for the use of antiemetics in anticancer therapy recently published by ASCO (American Society of Clinical Oncology)...
  65. pmc Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes
    D Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Clin Exp Immunol 154:360-4. 2008
    ....
  66. ncbi Prevention of delayed emesis induced by moderately emetogenic chemotherapy in patients with acute emesis: a pilot study with ACTH-Depot plus tropisetron
    D Santini
    Campus Bio-Medico University, Rome, Italy
    Med Oncol 18:131-5. 2001
    ..Moreover, no toxic effects were observed. These promising results require confirmation by a randomized trial...
  67. doi PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
    Fotios Loupakis
    Department of Oncology, Azienda USL 6, Istituto Toscano Tumori, Livorno, Italy
    J Clin Oncol 27:2622-9. 2009
    ..This retrospective study investigated the role of PTEN loss, AKT phosphorylation, and KRAS mutations on the activity of cetuximab plus irinotecan in patients with metastatic colorectal cancer (mCRC)...
  68. ncbi Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients
    Bruno Vincenzi
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    J Interferon Cytokine Res 25:144-51. 2005
    ....
  69. pmc Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
    F Graziano
    Medical Oncology, Azienda Ospedaliera Ospedale San Salvatore, Pesaro, Italy
    Br J Cancer 99:716-21. 2008
    ..Liver-only MCRC patients are a homogeneous and clinical relevant subgroup that may represent an ideal setting for studying the actual influence of TS polymorphisms...
  70. ncbi New perspectives: role of sunitinib in breast cancer
    M E Fratto
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    Clin Ter 161:475-82. 2010
    ..We overviewed the most relevant studies concerning sunitinib in metastatic BC...
  71. ncbi Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity
    S Galluzzo
    University Campus Bio Medico, Medical Oncology, Via Emilio Longoni 69, 00155 Rome, Italy
    Expert Opin Ther Targets 11:941-54. 2007
    ..All these unexpected effects of N-BPs on the immune system have opened new and intriguing possibilities of therapeutic use for these drugs...
  72. ncbi Chemotherapy in biliary tract cancer
    G Tonini
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    Eur Rev Med Pharmacol Sci 14:371-4. 2010
    ..Only few randomized trials with few patients have been conducted to in this setting of patients and standard chemotherapy has not been established yet...
  73. ncbi Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma
    A Baldi
    Laboratory of Cell Metabolism and Pharmacokinetics, Center for Experimental Research, Regina Elena Cancer Institute, Rome, Italy
    J Cell Biochem 83:364-72. 2001
    ..We conclude that changes in the expression of these proteins are involved in the later phases of melanoma progression, and may be responsible for the transition from local invasive melanoma to metastasis...
  74. ncbi Unusual presentation of Hodgkin's disease mimicking inflammatory bowel disease
    B Vincenzi
    , Via Longoni, 83, 00155 Rome, Italy
    Leuk Lymphoma 42:521-6. 2001
    ..The case and the differential diagnosis with other pathological entities of the bowel is discussed...
  75. doi Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    J Cell Physiol 223:384-8. 2010
    ..Immunohistochemistry for the hENT1 protein carries prognostic information in patients with resected gastric cancer and holds promise as a predictive factor in chemotherapy decisions...
  76. ncbi Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect
    F Salvinelli
    Area of Otolaryngology, University Campus Bio Medico, Rome, Italy
    J Exp Clin Cancer Res 22:155-8. 2003
    ..Hearing monitoring should be mandatory to evaluate the real incidence of clinical and sub-clinical hearing modification induced by carboplatin and paclitaxel based chemotherapy...
  77. ncbi Atypical chronic head and neck pain: don't forget Eagle's syndrome
    M Casale
    Area of Otolaryngology, University Campus Bio Medico, Rome, Italy
    Eur Rev Med Pharmacol Sci 12:131-3. 2008
    ..Medical treatment represents the first choice, followed by surgical styloid process resection, in the case of persistence or ingravescence of the complaint...
  78. ncbi Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Via Emilio Longoni 83, 00155 Rome, Italy
    Med Oncol 21:59-66. 2004
    ..Survival evaluation was considered a secondary endpoint...
  79. ncbi Pamidronate induces modifications of circulating angiogenetic factors in cancer patients
    Daniele Santini
    Università Campus Bio Medico, 00155 Rome, Italy
    Clin Cancer Res 8:1080-4. 2002
    ..The purpose of this study was to evaluate the modifications in angiogenic cytokines levels after pamidronate infusion. EXPERIMENTAl..
  80. doi Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome
    Bruno Vincenzi
    Department of Medical Oncology, Laboratory Medicine, and Radiology, University Campus Bio Medico, Rome, Italy
    Clin Cancer Res 14:4219-24. 2008
    ..We designed this trial to investigate if Mg(2+) serum level modifications may be related with clinical response and outcome in advanced colorectal cancer patients during treatment with cetuximab plus irinotecan...
  81. ncbi Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy
    Daniele Santini
    Medical Oncology Unit, University Campus Bio Medico, Rome, Italy
    Oncology 67:135-42. 2004
    ..We retrospectively evaluated the relevance of thymidylate synthase (TS) expression in normal colonic mucosa as a predictive factor of toxicity in colorectal cancer patients receiving adjuvant fluorouracil (5-FU)-based chemotherapy...
  82. doi Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial
    Bruno Vincenzi
    Department of Medical Oncology, Campus Bio Medico University, Rome, Italy
    Cancer 115:4849-56. 2009
    ..The aim of the current study was the investigation of the value of bevacizumab+5-fluorouracil(5-FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options...
  83. ncbi Docetaxel induced pericardial effusion
    B Vincenzi
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    J Exp Clin Cancer Res 26:417-20. 2007
    ..In the majority of cases its manifestations are edema or pleural effusion. We report two cases of patients who developed repeated episodes of pericardial effusion after docetaxel infusion...
  84. ncbi 'Internal bracing' surgery in the management of solid tumor metastases of the thoracic and lumbar spine
    Alberto Di Martino
    Department of Orthopaedics and Trauma Surgery, University Campus Bio Medico, Rome 00155, Italy
    Oncol Rep 21:431-5. 2009
    ....
  85. doi Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer
    Bruno Vincenzi
    Division of Medical Oncology, University Campus Bio Medico of Rome, Rome, Italy
    Nat Clin Pract Oncol 5:455-65. 2008
    ..We discuss the rationale for tailoring anticancer treatment in patients with colorectal cancer according to individual molecular and clinical features, with the aim of improving response rates and reducing the incidence of toxic events...
  86. doi Targeted therapy in biliary tract cancer: 2009 update
    Giuseppe Tonini
    Department of Medical Oncology, University Campus Bio Medico, 00128 Rome, Italy
    Future Oncol 5:1675-84. 2009
    ..The ongoing trials are also analyzed. In fact, only the results of these trials will establish which is the most effective agent or combination for this setting...
  87. doi Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients
    Bruno Vincenzi
    University Campus Bio Medico, Medical Oncology, Rome, Italy
    Expert Opin Biol Ther 9:945-9. 2009
    ..The aim of this study was to evaluate the effect of cigarette smoking on cetuximab efficacy in advanced colorectal cancer patients...
  88. doi The biological properties of cetuximab
    Bruno Vincenzi
    Medical Oncology, Campus Bio Medico University, Via Alvaro del Portillo 200, Rome, Italy
    Crit Rev Oncol Hematol 68:93-106. 2008
    ..This paper will overview all the experimental and pre-clinical data on the biological properties of cetuximab...
  89. doi The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen
    Bruno Vincenzi
    University Campus Bio Medico, Medical Oncology, Via Alvaro del Portillo 200, 00128 Rome, Italy
    Expert Opin Drug Saf 10:345-9. 2011
    ..S-Adenosyl methionine (AdoMet) supplementation is effective in the treatment of a variety of liver injuries, but it has never been evaluated in the prevention of chemotherapy-induced liver damage...
  90. ncbi Bisphosphonate anticancer activity
    Giuseppe Tonini
    University Campus Bio Medico, Department of Medical Oncology, Rome, Italy
    Expert Opin Pharmacother 12:681-3. 2011
    ..The results from clinical trials indicate the importance of treating and preventing bone metastases in many different cancer populations...
  91. ncbi Statins may potentiate bisphosphonates anticancer properties: a new pharmacological approach?
    Bruno Vincenzi
    Oncology Hematology Department, Campus Bio Medico University, Rome, Italy
    Med Hypotheses 61:98-101. 2003
    ....
  92. doi Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives
    Bruno Vincenzi
    University Campus Bio Medico, Medical Oncology, Via Alvaro del Portillo 200, 00128 Rome, Italy
    Pharmacogenomics 11:865-78. 2010
    ....
  93. doi In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Cancer Immunol Immunother 58:31-8. 2009
    ..The aim of our study was to evaluate the immunomodulating properties of a single-dose of zoledronic acid (ZA) on gammadelta T cells in a select group of disease-free breast cancer patients with osteopenia...
  94. ncbi Hormono-biological therapy in metastatic breast cancer: preclinical evidence, clinical studies and future directions
    Giuseppe Tonini
    University Campus Bio Medico, Medical Oncology, Via Emilio Longoni, 83 00155 Rome, Italy
    Expert Opin Biol Ther 8:221-34. 2008
    ..Ongoing clinical trials promise to further improve the present care for breast cancer patients...
  95. ncbi Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan
    Bruno Vincenzi
    University Campus Bio Medico, Medical Oncology, Via Emilio Longoni, 69, 00155, Rome, Italy
    Pharmacogenomics 8:319-27. 2007
    ....
  96. ncbi Antiangiogenic properties of metronomic chemotherapy in breast cancer
    Giuseppe Tonini
    Medical Oncology, University Campus Bio Medico, Rome, Via Emilio Longoni 83, 00155, Rome, Italy
    Future Oncol 3:183-90. 2007
    ..This review aims to explain the rationale behind metronomic and targeted therapies in breast cancer and to examine the main preclinical and clinical (neoadjuvant, adjuvant and advanced settings) studies conducted...
  97. ncbi Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients
    Daniele Santini
    Medical Oncology, Department of Laboratory Medicine, Campus Bio Medico University, 00155 Rome, Italy
    Clin Cancer Res 9:2893-7. 2003
    ..The patients were prospectively evaluated for circulating levels of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) just before and at 1, 2, 7, and 21 days after zoledronic acid infusion...
  98. ncbi Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade
    Giuseppe Perrone
    Department of Surgical Pathology, Campus Bio Medico University, Rome, Italy
    Mod Pathol 20:344-51. 2007
    ..This suggests reelin may behave as a specific histological marker and may represent a useful biomarker to predict aggressive phenotypic behavior of prostatic cancer cells...
  99. doi New therapies in soft tissue sarcoma
    Bruno Vincenzi
    University Campus Bio Medico, Medical Oncology, Via Alvaro del Portillo, 200, 00128, Rome, Italy
    Expert Opin Emerg Drugs 15:237-48. 2010
    ..Despite the efforts, overall 5-year survival rate in patients with soft tissue sarcomas of all stages remains only 50 - 60%...
  100. ncbi A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid
    Carlo C Quattrocchi
    Department of Radiology, Centro Interdisciplinare per la Ricerca Bio Medica, Via Longoni 47, 00155, Rome, Italy
    Skeletal Radiol 36:1121-7. 2007
    ..The objective was to prospectively determine CT density changes in bone metastases, before and after intravenous zoledronic acid for a maximum period of 12 months...
  101. ncbi The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies
    Bruno Vincenzi
    University Campus Bio Medico, Medical Oncology, Via Emilio Longoni 69, 00155, Rome, Italy
    Expert Opin Emerg Drugs 11:665-83. 2006
    ..This clinical review focuses on the defining role of the two most clinically advanced novel agents, bevacizumab and cetuximab in metastatic colorectal cancer...